Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Cancer genomes contain vast amounts of somatic mutations, many of which are passenger mutations not involved in oncogenesis. Whereas driver mutations in protein-coding genes can be distinguished from passenger mutations based on their recurrence, non-coding mutations are usually not recurrent at the same position. Therefore, it is still unclear how to identify cis-regulatory driver mutations, particularly when chromatin data from the same patient is not available, thus relying only on sequence and expression information. Here we use machine-learning methods to predict functional regulatory regions using sequence information alone, and compare the predicted activity of the mutated region with the reference sequence. This way we define the Predicted Regulatory Impact of a Mutation in an Enhancer (PRIME). We find that the recently identified driver mutation in the TAL1 enhancer has a high PRIME score, representing a "gain-of-target" for MYB, whereas the highly recurrent TERT promoter mutation has a surprisingly low PRIME score. We trained Random Forest models for 45 cancer-related transcription factors, and used these to score variations in the HeLa genome and somatic mutations across more than five hundred cancer genomes. Each model predicts only a small fraction of non-coding mutations with a potential impact on the function of the encompassing regulatory region. Nevertheless, as these few candidate driver mutations are often linked to gains in chromatin activity and gene expression, they may contribute to the oncogenic program by altering the expression levels of specific oncogenes and tumor suppressor genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes
Siepel, A., Bejerano, G., Pedersen, J. S., Hinrichs, A. S., Hou, M., Rosenbloom, K., Clawson, H., Spieth, J., Hillier, L. W., Richards, S., et al. (2005) · Genome Research · doi:10.1101/gr.3715005 · Cited by 3,971 · cited 1×
“Bigwig file with phastCons scores [69] based on alignment of 46 placental mammal species was downloaded from UCSC Genome Browser.”
MethodAnnotation of functional variation in personal genomes using RegulomeDB
Boyle, A. P., Hong, E. L., Hariharan, M., Cheng, Y., Schaub, M. A., Kasowski, M., Karczewski, K. J., Park, J., Hitz, B. C., Weng, S., et al. (2012) · Genome Research · doi:10.1101/gr.137323.112 · Cited by 2,722
Inferring Regulatory Networks from Expression Data Using Tree-Based Methods
Huynh-Thu, V. A., Irrthum, A., Wehenkel, L., & Geurts, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012776 · Cited by 2,131
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 3×
“The TERT promoter harbors two recurrent mutations and these are among the highest recurring mutations in cancer (between 33% and 85% in melanoma [2]).”
BackgroundThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443
Transcriptional enhancers: from properties to genome-wide predictions
Shlyueva, D., Stampfel, G., & Stark, A. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3682 · Cited by 1,356
Frequency of TERT promoter mutations in human cancers
Vinagre, J., Almeida, A., Pópulo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms3185 · Cited by 898
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., et al. (2014) · Science · doi:10.1126/science.1259037 · Cited by 801 · cited 4×
“Recently two cancer-related CRM mutations have been discovered, namely: a highly recurrent mutation in the TERT promoter that is found in many cancer types [2 – 5]; and a more distally located enhancer mutation upstream of the TAL1 gene in T-cell acute lymphoblastic leukemia (T-ALL) [6].”
BackgroundMethodInfluentialMelanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756 · cited 1×
“We then scored a large collection of real non-coding somatic mutations collected from three cancer whole genome sequencing studies: 50 AML samples (N = 19797) [35], 21 breast cancer samples (N = 183703) [37], and 25 melanoma samples (N = 1875157) [38].”
BackgroundThe transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7683 · Cited by 489
Self-citationGenome-wide analysis of noncoding regulatory mutations in cancer
Weinhold, N., Jacobsen, A., Schultz, N., Sander, C., & Lee, W. (2014) · Nature Genetics · doi:10.1038/ng.3101 · Cited by 484 · cited 1×
“This is indeed corroborated with the low number of cis-regulatory mutations that are found to be recurrent across cancer samples [7,45].”
BackgroundThe haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line
Adey, A., Burton, J. N., Kitzman, J. O., Hiatt, J. B., Lewis, A. P., Martin, B. K., Qiu, R., Lee, C., & Shendure, J. (2013) · Nature · doi:10.1038/nature12064 · Cited by 362 · cited 2×
“The low number of high-impact mutations was again confirmed when we scored insertions found in the HeLa genome (scoring 10 kb regions around TSS) [42,43], where we found only one insertion (near CDH10 ) with high impact and associated with a gain in H3K27Ac signal (as the reported insertion in the…”
BackgroundMethodTERT promoter mutations and telomerase reactivation in urothelial cancer
Borah, S., Xi, L., Zaug, A. J., Powell, N. M., Dancik, G. M., Cohen, S. B., Costello, J. C., Theodorescu, D., & Cech, T. R. (2015) · Science · doi:10.1126/science.1260200 · Cited by 292
Gotea, V., Visel, A., Westlund, J. M., Nobrega, M. A., Pennacchio, L. A., & Ovcharenko, I. (2010) · Genome Research · doi:10.1101/gr.104471.109 · Cited by 248 · cited 1×
“This is mostly due to the context of the CRM, for example, when multiple binding sites of the same factor are present in a CRM (i.e., a homotypic cluster [55]), adding or deleting a single binding site may not have any dramatic effect on the CRM.”
BackgroundTERT promoter mutations in cancer development
Heidenreich, B., Rachakonda, P. S., Hemminki, K., & Kumar, R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.005 · Cited by 238
i-cisTarget 2015 update: generalized cis-regulatory enrichment analysis in human, mouse and fly
Imrichová, H., Hulselmans, G., Kalender Atak, Z., Potier, D., & Aerts, S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv395 · Cited by 202 · cited 6×
“We define functional peaks as the signficant subset (or “ leading edge ” [28]) of peaks that are located near genes that are up-or down-regulated upon perturbation of the TF. Compared to previous methods that often rely on k-mers, Markov chains, or de novo discovered motifs in the training set…”
MethodInfluentialGenome-wide prediction of transcription factor binding sites using an integrated model
Won, K.-J., Ren, B., & Wang, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-1-r7 · Cited by 116 · cited 3×
“Corroborating previous work by others [25,49,54], such models have a higher performance compared to sequence-based prediction methods.”
MethodResultComputational methods for the detection of cis-regulatory modules
Van Loo, P., & Marynen, P. (2009) · Briefings in Bioinformatics · doi:10.1093/bib/bbp025 · Cited by 62 · cited 1×
“We expected an increased specificity (rather than sensitivity) of mutation detection with Random Forest models (M1) compared to the simple PWM model (M0), because PWMs are known to suffer from high false positive rates [36].”
Background
Cited by
DeepSTARR predicts enhancer activity from DNA sequence and enables the de novo design of enhancers
de Almeida, B. P., Reiter, F., Pagani, M., & Stark, A. (2021) · doi:10.1101/2021.10.05.463203 · Cited by 284
de Almeida, B. P., Reiter, F., Pagani, M., & Stark, A. (2022) · Nature Genetics · doi:10.1038/s41588-022-01048-5 · Cited by 283
Jacobs, J., Atkins, M., Davie, K., Imrichova, H., Romanelli, L., Christiaens, V., Hulselmans, G., Potier, D., Wouters, J., Taskiran, I. I., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0140-x · Cited by 155
Self-citationInterpretation of allele-specific chromatin accessibility using cell state–aware deep learning
Atak, Z. K., Taskiran, I. I., Demeulemeester, J., Flerin, C., Mauduit, D., Minnoye, L., Hulselmans, G., Christiaens, V., Ghanem, G.-E., Wouters, J., et al. (2021) · Genome Research · doi:10.1101/gr.260851.120 · Cited by 48
“Models including support vector machines (Ghandi et al. 2014; Svetlichnyy et al. 2015) and neural networks (Alipanahi et al. 2015; Zhou and Troyanskaya 2015; Kelley et al. 2016; Liu et al. 2018) can be trained on enhancer sequences and used to predict the impact of mutations.”
BackgroundMethodSelf-citationSchwessinger, R., Suciu, M. C., McGowan, S. J., Telenius, J., Taylor, S., Higgs, D. R., & Hughes, J. R. (2017) · Genome Research · doi:10.1101/gr.220202.117 · Cited by 35
Metadata
- Authors
- Svetlichnyy, D., Imrichova, H., Fiers, M., Kalender Atak, Z., & Aerts, S.
- Venue
- PLOS Computational Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-12
- Volume
- 11
- Issue
- 11
- Pages
- e1004590
- ISSN
- 1553-734X (ISSN-L)
- 1553-7358
- OpenAlex
- W2178844003
- Cited by
- 22
- References
- 19
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.